Key Takeaways
- Nvidia (NVDA) authorized a record-breaking $150 billion increase to its share repurchase program, the largest in corporate history.
- US Crude Futures (WTI) jumped over 4% to a session peak of $96.44 per barrel following the collapse of peace negotiations between the U.S. and Iran.
- UK authorities foiled a suspected terror attack at RAF Fairford, a base used by U.S. bombers for strikes in the Middle East, leading to five arrests.
- Merck (MRK) entered a $2.13 billion licensing deal with SciBrunch Therapeutics for a promising oral KRAS G12D inhibitor for cancer treatment.
- The European Commission proposed a one-year postponement of its methane regulation to protect energy security amid ongoing regional conflicts.
Nvidia (NVDA) dominated market headlines today by announcing a massive $150 billion increase to its share buyback authorization. This historic move brings the company's total remaining repurchase capacity to $235 billion. Management noted that the decision reflects confidence in the long-term demand for AI data center infrastructure, with plans to return at least 50% of free cash flow to shareholders through dividends and buybacks.
Global energy markets reacted sharply to deteriorating diplomatic relations as US Crude Futures surged past $96 per barrel. The spike followed reports that President Trump rejected a peace proposal from Iran intended to reopen the Strait of Hormuz. Market analysts warn that the stalemate keeps a significant geopolitical risk premium embedded in oil prices, especially as the market continues to operate in a supply deficit.
In the United Kingdom, counterterrorism police arrested five men near RAF Fairford on suspicion of preparing a terrorist act involving explosives. The base is a critical forward operating location for U.S. Air Force B-1B Lancer bombers currently engaged in regional strikes. Security at the installation had been heightened for days prior to the arrests, which President Trump described as a "fantastic" joint effort between U.S. and British intelligence.
Pharmaceutical giant Merck (MRK) expanded its oncology pipeline through an exclusive global license agreement with SciBrunch Therapeutics. The deal, valued at up to $2.13 billion, focuses on SPR2015, an investigational oral inhibitor targeting the KRAS G12D mutation common in pancreatic and colorectal cancers. Merck will pay an upfront fee of $400 million, which will be recorded as a pre-tax charge in its third-quarter results.
Central bank activity remained in focus as Bank of England Deputy Governor Dave Ramsden noted that food price inflation has been "weaker than expected." Despite this, the BoE is moving forward with plans to unwind its balance sheet, announcing the sale of £146 billion in gilts back to the Treasury at a pace of £20 billion per year. Simultaneously, the European Commission is weighing a delay to its methane emissions law until 2028 to avoid further straining energy prices during the current Middle East crisis.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.